Please provide your email address to receive an email when new articles are posted on . Outset Medical, maker of the Tablo hemodialysis machine, reported that the device was added to 30 new hospital ...

Please provide your email address to receive an email when new articles are posted on . A lengthy review by the FDA of 510(k)-related updates to Outset Medical’s Tablo home dialysis machine has halted ...

After kicking off the year by shipping out a record number of its Tablo hemodialysis systems for at-home users, Outset Medical has brought those sales to a screeching halt. The California-based ...

Outset Medical has raised $76.5 million in a series C round led by T. Rowe Price Associates. In addition to new investor T. Rowe Price Associates, existing investors Fidelity Management & Research ...

About a month and a half after pausing shipments of its Tablo hemodialysis system for at-home use, Outset Medical has secured the renewed FDA clearance it was waiting for, greenlighting new sales of ...

Outset Medical (OM) has received a new Buy rating, initiated by BTIG analyst, Marie Thibault. Marie Thibault’s rating is based on a variety of positive indicators for Outset Medical, despite some ...

Outset Medical, Inc. (NASDAQ:OM) is commercializing a new hemodialysis machine for acute care and home settings. I previously wrote about OM with a Hold outlook. The company has reduced guidance due ...

Outset Medical (NASDAQ:OM), the innovator behind the Tablo Hemodialysis System, reported fourth-quarter earnings on Wednesday, Feb. 19, that topped analysts' consensus expectations on top and bottom ...